These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11992628)

  • 21. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
    Cummings J; Macpherson JS; Meikle I; Smyth JF
    Biochem Pharmacol; 1996 Oct; 52(7):979-90. PubMed ID: 8831716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
    Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
    Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
    Gupta E; Wang X; Ramirez J; Ratain MJ
    Cancer Chemother Pharmacol; 1997; 39(5):440-4. PubMed ID: 9054958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
    Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
    Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes.
    Haaz MC; Rivory L; Jantet S; Ratanasavanh D; Robert J
    Pharmacol Toxicol; 1997 Feb; 80(2):91-6. PubMed ID: 9060040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irinotecan (CPT-11) metabolites in human bile and urine.
    Lokiec F; du Sorbier BM; Sanderink GJ
    Clin Cancer Res; 1996 Dec; 2(12):1943-9. PubMed ID: 9816153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
    Mallick P; Shah P; Gandhi A; Ghose R
    Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
    Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
    Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
    Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.
    Boyd G; Smyth JF; Jodrell DI; Cummings J
    Anal Biochem; 2001 Oct; 297(1):15-24. PubMed ID: 11567523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irinotecan (CPT-11) metabolism and disposition in cancer patients.
    Sparreboom A; de Jonge MJ; de Bruijn P; Brouwer E; Nooter K; Loos WJ; van Alphen RJ; Mathijssen RH; Stoter G; Verweij J
    Clin Cancer Res; 1998 Nov; 4(11):2747-54. PubMed ID: 9829738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
    Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
    Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes.
    Hanioka N; Jinno H; Nishimura T; Ando M; Ozawa S; Sawada J
    Biomed Chromatogr; 2001 Aug; 15(5):328-33. PubMed ID: 11507714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.
    Tallman MN; Ritter JK; Smith PC
    Drug Metab Dispos; 2005 Jul; 33(7):977-83. PubMed ID: 15833930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
    Sparreboom A; de Bruijn P; de Jonge MJ; Loos WJ; Stoter G; Verweij J; Nooter K
    J Chromatogr B Biomed Sci Appl; 1998 Aug; 712(1-2):225-35. PubMed ID: 9698245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
    Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Brangi M; Litman T; Ciotti M; Nishiyama K; Kohlhagen G; Takimoto C; Robey R; Pommier Y; Fojo T; Bates SE
    Cancer Res; 1999 Dec; 59(23):5938-46. PubMed ID: 10606239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.